I want to bring attention to a peptide that doesn't get enough discussion here: KPV (Lys-Pro-Val), a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH).

Why it's relevant to this community: many GLP-1 RA users deal with GI inflammation, and a subset have pre-existing IBD (Crohn's, UC) where the GI side effects of semaglutide/tirzepatide can be particularly problematic. KPV is one of the more promising anti-inflammatory peptides specifically targeting intestinal inflammation.

Key research:

• Dalmasso et al. (2008, PMID: 18316394) — KPV reduced colonic inflammation in a mouse model of colitis via inhibition of NF-κB activation and inflammatory cytokine secretion. Published in PNAS.
• Kannengiesser et al. (2008, PMID: 17932232) — melanocortin peptides including KPV showed anti-inflammatory effects in DSS-induced colitis model.
• Laroui et al. (2010, PMID: 20637790) — demonstrated that KPV loaded into nanoparticles could be delivered orally and effectively reduced colonic inflammation.

The Dalmasso paper is particularly interesting because it showed KPV works intracellularly — it crosses the cell membrane and directly inhibits NF-κB activation by preventing IκBα phosphorylation. This is a different mechanism than most anti-inflammatory peptides.

I've been following KPV research for about two years now. A few additional points:

What makes KPV special compared to full-length α-MSH is its simplicity and specificity. α-MSH has multiple biological activities — melanogenesis, anti-inflammatory, antipyretic, appetite suppression (via MC4R). The KPV tripeptide retains the anti-inflammatory activity but loses the melanocortin receptor binding. This means:

• No skin darkening/tanning effect
• No appetite effects (won't interfere with your GLP-1 RA)
• Retained anti-inflammatory mechanism via direct NF-κB inhibition

The fact that a mere tripeptide (three amino acids!) can cross cell membranes and modulate NF-κB signaling is remarkable. It's also incredibly stable for a peptide — being only three residues long, there's very little to degrade.

many GLP-1 RA users deal with GI inflammation

Exactly. And for the IBD patients on GLP-1 RAs, the standard advice of "titrate slowly and it'll get better" doesn't always apply. Their baseline gut is already compromised. KPV could be a useful adjunct in this specific population.

I have mild-to-moderate UC (diagnosed 2021, currently on mesalamine 4.8 g/day). Started semaglutide 3 months ago for weight management and have had a partial UC flare — increased frequency, some blood. My GI doc adjusted my mesalamine but I'm looking for additional options.

Is KPV something I could reasonably add? What route and dose? And would it interact with mesalamine?

First, the important caveat: you're dealing with a diagnosed IBD condition, so any additions should ideally be discussed with your GI doc. That said, I understand the reality that most GI docs won't be familiar with KPV.

On interactions: mesalamine works primarily as a topical anti-inflammatory in the colon via inhibition of prostaglandin and leukotriene synthesis (COX and LOX pathways). KPV works via NF-κB inhibition. These are different mechanisms and there's no theoretical basis for a negative interaction. If anything, they could be complementary — hitting inflammation from two different angles.

Current protocols being used in the research peptide community:

• Oral: 500-1000 mcg daily, typically in capsule form, taken on an empty stomach
• Subcutaneous: 200-500 mcg daily
• For GI-specific indications: oral route is preferred for local delivery to intestinal mucosa

The Laroui nanoparticle study is interesting because it demonstrated that oral KPV can survive the GI tract and reach the colon. As a tripeptide, it's more resistant to enzymatic degradation than larger peptides, but nanoparticle encapsulation improved colonic delivery in the mouse model.

This is interesting but how available is KPV? I haven't seen it at any of the suppliers I normally use for research peptides. Is it hard to find?